Selinexor, methotrexate, and rituximab with radiation for new CNS lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (selinexor, high-dose methotrexate, and rituximab) plus radiation for people with newly diagnosed central nervous system (CNS) lymphoma who cannot have a stem cell transplant. The goal is to see if this treatment can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of primary CNS lymphoma or secondary CNS lymphoma that is only in the brain or spinal cord.
- You are not eligible for a stem cell transplant (or choose not to have one).
- You have at least one brain tumor that can be measured, or cancer cells in your spinal fluid.
- You are generally able to take care of yourself (ECOG score of 0-3).
- Your kidney and liver function are adequate, and your blood counts are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, zanubrutinib, combined with standard chemotherapy for people recently diagnosed with primary central nervous system lymphoma (a type of brain cancer). It aims to see if this combination is safe and effective.
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
This trial tests a combination of drugs (Orelabrutinib and Selinexor) with either Methotrexate, Thiotepa, or Temozolomide for people whose brain lymphoma has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
This trial tests selinexor given together with methotrexate and rituximab to treat lymphoma that has returned or not responded in the brain. It may help by attacking cancer cells in the central nervous system (brain/spinal fluid) after prior treatment.
Hear when a new Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.